Practice
Featured experience
Bristol Myers Squibb $13 billion notes offering
The investment-grade offering comprised nine tranches
Cisco Systems $13.5 billion notes offering
The investment-grade offering comprises seven tranches of notes
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Novartis $3.7 billion notes offering
We advised Novartis on the investment-grade debt offering
Amer Sports $1.05 billion follow-on offering
We advised Amer Sports on its SEC-registered offering
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
PG&E $2.76 billion common and preferred share offerings
The common stock is, and the preferred stock will be, listed on the NYSE
indie Semiconductor $218.5 million convertible senior notes offering
The 3.5% convertible senior notes are due 2029
Fastly $150 million convertible senior notes offering
The 7.75% convertible notes are due 2028
Enviva emerges from chapter 11
We advised an ad hoc group of creditors in connection with Enviva’s chapter 11 proceedings
PAR Technology private exchange
$100 million aggregate principal amount of existing convertible senior notes were exchanged
Sitios $650 million senior notes offering
The 6% notes are due 2029
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Pony AI $413 million IPO
We advised Pony AI on its IPO, concurrent private placements and Nasdaq listing